Table 4.
Summary of ongoing copanlisib studies
| Treatment(s) | Indication | Phase | Study name | Status | Country | NCT identifier |
|---|---|---|---|---|---|---|
| Copanlisib | NHL | I | Active, not recruiting | China | NCT03498430 | |
| Copanlisib | Advanced solid tumor | I/II | Recruiting | US | NCT03735628 | |
| Copanlisib | NHL | III | CHRONOS-2 | Active, not recruiting | Multinational | NCT02369016 |
| Copanlisib | NHL | Ib/II | Active, not recruiting | Japan | NCT02342665 | |
| Copanlisib | Mixed malignant tumor | I/II | Recruiting | US | NCT03458728 | |
| Copanlisib | NHL | II | CHRONOS-1 | Active, not recruiting | Multinational | NCT01660451 |
| Copanlisib and ibrutinib | MCL | I/II | Active, not recruiting | US | NCT03877055 | |
| Copanlisib and rituximab | MZL | II | Recruiting | Austria, Germany | NCT03474744 | |
| Copanlisib and gemcitabine | Mature T cell and NK cell neoplasm | I/II | Active, not recruiting | Republic of Korea | NCT03052933 | |
| Copanlisib and nivolumab | Colorectal cancer | I/II | Recruiting | US | NCT03711058 | |
| Copanlisib and rucaparib | Prostate cancer | I/II | Recruiting | US | NCT04253262 | |
| Copanlisib, bendamustine, and rituximab | Lymphoid leukemia, NHL, CLL, SLL | II | Recruiting | US | NCT04155840 | |
| Copanlisib and rituximab | NHL | III | CHRONOS-3 | Active, not recruiting | Multinational | NCT02367040 |
| Copanlisib and standard immunochemotherapy | NHL | III | CHRONOS-4 | Active, not recruiting | Multinational | NCT02626455 |
| Copanlisib, gemcitabine, carboplatin, dexamethasone, rituximab, and pegfilgrastim | DLBCL, FL | Ib | Recruiting | US | NCT04156828 | |
| Copanlisib and rogaratinib | Advanced or metastatic solid tumor | I | Active, not recruiting | Multinational | NCT03517956 | |
| Copanlisib, gemcitabine, and cisplatin | Cholangiocarcinoma | II | Active, not recruiting | US | NCT02631590 |
CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma, FL follicular lymphoma, MCL mantle cell lymphoma, MZL marginal zone lymphoma, NHL non-Hodgkin lymphoma, NK natural killer, SLL small lymphocytic lymphoma